BIOMAT Database Logo BIOMAT Database Logo

Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model. 1996

P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Centre de Recherche en Infectiologie, Centre Hospitalier de l'Université Laval, QC, Canada.

The efficacy and toxicity of ribavirin (25 or 125 mg/kg/day), 2',3'-dideoxyinosine (ddI) (200 mg/kg/day) and a combination of both drugs at these doses given for 6 weeks were investigated in the murine acquired immunodeficiency syndrome model. Our results showed a significant protection against splenomegaly, lymphadenopathy and hypergammaglobulinemia in mice treated with ribavirin at 25 mg/kg/day alone or in combination with ddI at 200 mg/kg/day. A good synergistic effect was observed with the drug combination, whereas ddI alone (200 mg/kg/day) did not give any protection. Ribavirin/ddI combination protected against the loss of CD8 T cells in spleen and restored the capacity of splenocytes to proliferate after activation with a mitogenic agent. Moreover, the drug combination resulted in a protection of the spleen and cervical lymph node architectures and a regression of germinal centers. Hematotoxicity appeared at a dose of 125 mg/kg of ribavirin alone and increased when used concomitantly with ddI. In conclusion, ribavirin and ddI at low doses are synergistic and effective in the murine acquired immunodeficiency disease model, but at high doses they are toxic.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008206 Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. Lymphatism,Status Lymphaticus,Disease, Lymphatic,Diseases, Lymphatic,Lymphatic Disease
D008221 Lymphoid Tissue Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS. Lymphatic Tissue,Lymphatic Tissues,Lymphoid Tissues,Tissue, Lymphatic,Tissue, Lymphoid,Tissues, Lymphatic,Tissues, Lymphoid
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012254 Ribavirin A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. Ribovirin,Tribavirin,ICN-1229,Rebetol,Ribamide,Ribamidil,Ribamidyl,Ribasphere,Vilona,Viramide,Virazide,Virazole,ICN 1229,ICN1229

Related Publications

P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome.
June 1992, The American journal of gastroenterology,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
[Dideoxycytidine and dideoxyinosine: new therapy for acquired immunodeficiency syndrome?].
July 1991, Harefuah,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
January 1992, American journal of ophthalmology,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
May 1990, The New England journal of medicine,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.
November 1991, The Journal of biological chemistry,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
5-Amino-4-imidazolecarboxamide riboside potentiates the metabolism and anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine.
July 1993, Molecular pharmacology,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Pulmonary hypertension in a murine model of the acquired immunodeficiency syndrome.
July 1994, American journal of respiratory and critical care medicine,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
[Animal model of human AIDS: murine acquired immunodeficiency syndrome virus].
September 1993, Nihon rinsho. Japanese journal of clinical medicine,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
May 1994, British journal of clinical pharmacology,
P Harvie, and R F Omar, and N Dusserre, and N Lansac, and A Désormeaux, and P Gourde, and M Simard, and M Tremblay, and D Beauchamp, and M G Bergeron
Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.
May 1987, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!